<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02990936</url>
  </required_header>
  <id_info>
    <org_study_id>TGV-PI01</org_study_id>
    <nct_id>NCT02990936</nct_id>
  </id_info>
  <brief_title>Prognostic Impact of Tumor Growth Velocity in Head and Neck Squamous Cell Carcinoma Treated by Radio(Chemo)Therapy</brief_title>
  <acronym>TGV-PI</acronym>
  <official_title>Prognostic Impact of Tumor Growth Velocity in Head and Neck Squamous Cell Carcinoma Treated by Radio(Chemo)Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire UCLouvain Namur</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire UCLouvain Namur</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the impact of tumor growth velocity on the survival&#xD;
      of patients with hea and neck squamous cell carcinoma treated by (chemo-)radiotherapy.&#xD;
&#xD;
      Patients with stages I to IV oropharyngeal primary squamous cell carcinoma (OPSCC) elected&#xD;
      for radiotherapy or radiochemotherapy with curative intent will be selected. Tumor volume and&#xD;
      number and size of pathological neck lymph nodes (small diameter &gt; 1 cm) will be assessed on&#xD;
      diagnostic CT-scan (DiCT) and treatment planning CT-scan (RtCT) using the summation of areas&#xD;
      technique. Tumor progression and tumor doubling time will be calculated based on DiCT and&#xD;
      RtCT. Tumor proliferation will be assessed on biopsy specimens by Ki67 immunohistochemistry&#xD;
      and mitotic index. HPV status will be evaluated by PCR and p16 immunohistochemistry.&#xD;
      Ulcerative or exophytic aspect will be noticed. Tumoral kinetics patterns will be correlated&#xD;
      with disease free survival and overall survival of patients with HNSCC. These patterns will&#xD;
      be compared to HPV status and proliferation markers in order to study their clinical&#xD;
      signification [time frame: 5 years] and develop predictive markers of tumor progression for&#xD;
      head and neck cancers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Head and neck squamous cell carcinoma (HNSCC) represents more than 90 percent of head and&#xD;
      neck tumors and is one of the most frequent human neoplasms. During the last decades,&#xD;
      radiotherapy has emerged as a standard treatment of HNSCC and the number of patients treated&#xD;
      with this modality has continuously increased. Moreover, treatment schedules for radiotherapy&#xD;
      have improved and require more preparation and are therefore more time consuming. Thus,&#xD;
      waiting time prior to radiotherapy becomes a major concern in many countries with reported&#xD;
      delays of 70 days or even more.Clinicians involved in treating HNSCC face the problem of&#xD;
      rapidly growing tumors but despite significant progress in the understanding of these tumors,&#xD;
      their development and progression remain currently unpredictible at the time of diagnosis. In&#xD;
      a retrospective trial, Laccourreye et al. studied the time of progression of symptoms and&#xD;
      signs (TPSS) before diagnosis and treatment in 966 HNSCC cases and showed that for a given&#xD;
      tumor stage, the longer was the TPSS, the better were the vital prognosis, the local and&#xD;
      lymph node control. But there is no clear definition of fast growing tumor, with objective&#xD;
      measurement.&#xD;
&#xD;
      A CT-scan is perfomed at the time of diagnosis. Several weeks later, a second CT-scan is&#xD;
      necessary for treatment planning in order to define the tumoral target volume. This necessity&#xD;
      provides the opportunity to compare tumoral volumes on both exams, and thus to assess tumoral&#xD;
      progression. In a pilot study conducted with Institut Gustave Roussy, the investigators&#xD;
      studied retrospectively the tumor and loco-regional progression in the waiting time between&#xD;
      diagnostic and treatment planning CT-scans in a cohort of patients with oropharyngeal&#xD;
      squamous cell carcinoma, treated by radio(chemo)therapy between April 2005 and April 2007.&#xD;
      The study demonstrated that 53% of the patients presented a tumoral progression of &gt; 50%&#xD;
      within a mean waiting time of 42.1 +/- 15.7 days. The investigators consider this situation&#xD;
      as regrettable, and prospective trials are clearly needed to determine clinical consequences&#xD;
      of these findings.&#xD;
&#xD;
      The current project aims to study prospectively the loco-regional tumoral progression within&#xD;
      the waiting time between diagnostic and treatment planning CT-scans in a cohort of patients&#xD;
      with OPSCC. Patients with oropharyngeal primary squamous cell carcinoma elected for&#xD;
      radiotherapy or radiochemotherapy with curative intent will be selected. Tumor volume, number&#xD;
      and size of pathological cervical lymph nodes (small diameter &gt; 1 cm) will be assessed on&#xD;
      diagnostic CT-scan (DiCT) and treatment planning CT-scan (RtCT) using the summation of areas&#xD;
      technique (computerized delineation). Tumoral progression and tumor doubling time will be&#xD;
      calculated based on DiCT and RtCT in order to define different tumoral kinetics patterns.&#xD;
      Human papillomavirus (HPV) status will be assessed by polymerase chain reaction (PCR) and p16&#xD;
      immunohistochemistry. As primary objective, the investigators will study the tumoral kinetics&#xD;
      patterns with disease free survival (DFS) and overall survival (OS) in patients with OPSCC in&#xD;
      order to study their clinical signification [time frame: 5 years]. As secondary objectives,&#xD;
      the investigators will correlate the tumoral kinetics patterns with HPV status of patients&#xD;
      with OPSCC, and compare tumoural kinetics to proliferation markers (Ki67, mitotic index) in&#xD;
      order to develop predictive markers of tumour progression for head and neck cancers. An other&#xD;
      complementary objective will compare tumor kinetics patterns with endoscopic aspect&#xD;
      (ulcerative versus exophytic)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2019</start_date>
  <completion_date type="Anticipated">November 2026</completion_date>
  <primary_completion_date type="Anticipated">November 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>5 years follow-up after recruitment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>disease-free survival</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>correlation between kinetics patterns and HPV status</measure>
    <time_frame>5y follow-up</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>correlation between kinetics patterns and proliferation markers</measure>
    <time_frame>5y follow-up</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>correlation between kinetics patterns and endoscopic aspect of the tumor</measure>
    <time_frame>5y follow-up</time_frame>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <condition>Tumor Growth</condition>
  <arm_group>
    <arm_group_label>head and neck squamous cell carcinoma</arm_group_label>
    <description>Patients with T1 to T4 head and neck squamous cell carcinoma from oral cavity, oropharynx, larynx and hypopharynx eligible for radiotherapy or concomitant chemoradiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Tumor delineation</intervention_name>
    <description>Measurement of tumor volume and neck nodes volume on a diagnostic CT and a pre-treatment CT by computerized delineation in order to calculate tumor growth velocity and tumor doubling time and describe tumoral kinetics patterns</description>
    <arm_group_label>head and neck squamous cell carcinoma</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Oropharynx biopsy&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All T1 to T4 patients under eligibility criteria with head and neck squamous cell carcinoma&#xD;
        admitted to the investigators' tertiary centers will be selected.&#xD;
&#xD;
        Centre hospitalier Universitaire Godinne is a belgian provincial tertiary center.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  clinical and anatomopathological diagnosis of a head and neck squamous cell carcinoma&#xD;
             (T1 to T4) (oral cavity, oropharynx, larynx, hypopharynx)&#xD;
&#xD;
          -  multidisciplinary decision for radiotherapy or concomitant radiochemotherapy&#xD;
             eligibility&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  metastatic disease&#xD;
&#xD;
          -  primary surgical management&#xD;
&#xD;
          -  contraindications to iodine contrast injection: anaphylaxis and renal insufficiency&#xD;
&#xD;
          -  tumor not visible on CT&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sebastien Van der Vorst, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Dinant Godinne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sebastien Van der Vorst, MD, PhD</last_name>
    <phone>+32 81 423726</phone>
    <email>sebastien.vandervorst@uclouvain.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinique Ste-Elisabeth</name>
      <address>
        <city>Namur</city>
        <zip>5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Jean-Francois Daisne, MD,PhD</last_name>
      <phone>+32.81.720.757</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Dinant Godinne</name>
      <address>
        <city>Yvoir</city>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Sebastien Vandervorst, MD,PhD</last_name>
      <phone>+32 81 423726</phone>
      <email>sebastien.vandervorst@uclouvain.be</email>
    </contact>
    <investigator>
      <last_name>Gilles Delahaut, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sebastien Van der Vorst, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <reference>
    <citation>Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66. doi: 10.3322/canjclin.57.1.43.</citation>
    <PMID>17237035</PMID>
  </reference>
  <reference>
    <citation>Waaijer A, Terhaard CH, Dehnad H, Hordijk GJ, van Leeuwen MS, Raaymakers CP, Lagendijk JJ. Waiting times for radiotherapy: consequences of volume increase for the TCP in oropharyngeal carcinoma. Radiother Oncol. 2003 Mar;66(3):271-6. doi: 10.1016/s0167-8140(03)00036-7.</citation>
    <PMID>12742266</PMID>
  </reference>
  <reference>
    <citation>Jensen AR, Nellemann HM, Overgaard J. Tumor progression in waiting time for radiotherapy in head and neck cancer. Radiother Oncol. 2007 Jul;84(1):5-10. doi: 10.1016/j.radonc.2007.04.001. Epub 2007 May 9.</citation>
    <PMID>17493700</PMID>
  </reference>
  <reference>
    <citation>Brouha XD, Op De Coul B, Terhaard CH, Hordijk GJ. Does waiting time for radiotherapy affect local control of T1N0M0 glottic laryngeal carcinoma? Clin Otolaryngol Allied Sci. 2000 Jun;25(3):215-8. doi: 10.1046/j.1365-2273.2000.00347.x.</citation>
    <PMID>10944052</PMID>
  </reference>
  <reference>
    <citation>De Meerleer GO, Vakaet LA, De Gersem WR, De Wagter C, De Naeyer B, De Neve W. Radiotherapy of prostate cancer with or without intensity modulated beams: a planning comparison. Int J Radiat Oncol Biol Phys. 2000 Jun 1;47(3):639-48. doi: 10.1016/s0360-3016(00)00419-3.</citation>
    <PMID>10837946</PMID>
  </reference>
  <reference>
    <citation>Mackillop WJ, Zhou Y, Quirt CF. A comparison of delays in the treatment of cancer with radiation in Canada and the United States. Int J Radiat Oncol Biol Phys. 1995 May 15;32(2):531-9. doi: 10.1016/0360-3016(94)00662-5.</citation>
    <PMID>7751195</PMID>
  </reference>
  <reference>
    <citation>O'Rourke N, Edwards R. Lung cancer treatment waiting times and tumour growth. Clin Oncol (R Coll Radiol). 2000;12(3):141-4. doi: 10.1053/clon.2000.9139.</citation>
    <PMID>10942328</PMID>
  </reference>
  <reference>
    <citation>Primdahl H, Nielsen AL, Larsen S, Andersen E, Ipsen M, Lajer C, Vestermark LW, Andersen LJ, Hansen HS, Overgaard M, Overgaard J, Grau C; DAHANCA. Changes from 1992 to 2002 in the pretreatment delay for patients with squamous cell carcinoma of larynx or pharynx: a Danish nationwide survey from DAHANCA. Acta Oncol. 2006;45(2):156-61. doi: 10.1080/02841860500423948.</citation>
    <PMID>16546860</PMID>
  </reference>
  <reference>
    <citation>Robinson D, Massey T, Davies E, Jack RH, Sehgal A, Moller H. Waiting times for radiotherapy: variation over time and between cancer networks in southeast England. Br J Cancer. 2005 Apr 11;92(7):1201-8. doi: 10.1038/sj.bjc.6602463.</citation>
    <PMID>15785752</PMID>
  </reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>May 28, 2015</study_first_submitted>
  <study_first_submitted_qc>December 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2016</study_first_posted>
  <last_update_submitted>October 1, 2019</last_update_submitted>
  <last_update_submitted_qc>October 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hea and neck squamous cell carcinoma</keyword>
  <keyword>tumor growth</keyword>
  <keyword>predictive markers</keyword>
  <keyword>tumoral kinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02990936
org study id: TGV-PI01
nct id: NCT02990936
lead sponsor: 
has dmc: No
The purpose of this study is to determine the impact of tumor growth velocity on the survival
      of patients with hea and neck squamous cell carcinoma treated by (chemo-)radiotherapy.

      Patients with stages I to IV oropharyngeal primary squamous cell carcinoma (OPSCC) elected
      for radiotherapy or radiochemotherapy with curative intent will be selected. Tumor volume and
      number and size of pathological neck lymph nodes (small diameter > 1 cm) will be assessed on
      diagnostic CT-scan (DiCT) and treatment planning CT-scan (RtCT) using the summation of areas
      technique. Tumor progression and tumor doubling time will be calculated based on DiCT and
      RtCT. Tumor proliferation will be assessed on biopsy specimens by Ki67 immunohistochemistry
      and mitotic index. HPV status will be evaluated by PCR and p16 immunohistochemistry.
      Ulcerative or exophytic aspect will be noticed. Tumoral kinetics patterns will be correlated
      with disease free survival and overall survival of patients with HNSCC. These patterns will
      be compared to HPV status and proliferation markers in order to study their clinical
      signification [time frame: 5 years] and develop predictive markers of tumor progression for
      head and neck cancers.
Head and neck squamous cell carcinoma (HNSCC) represents more than 90 percent of head and
      neck tumors and is one of the most frequent human neoplasms. During the last decades,
      radiotherapy has emerged as a standard treatment of HNSCC and the number of patients treated
      with this modality has continuously increased. Moreover, treatment schedules for radiotherapy
      have improved and require more preparation and are therefore more time consuming. Thus,
      waiting time prior to radiotherapy becomes a major concern in many countries with reported
      delays of 70 days or even more.Clinicians involved in treating HNSCC face the problem of
      rapidly growing tumors but despite significant progress in the understanding of these tumors,
      their development and progression remain currently unpredictible at the time of diagnosis. In
      a retrospective trial, Laccourreye et al. studied the time of progression of symptoms and
      signs (TPSS) before diagnosis and treatment in 966 HNSCC cases and showed that for a given
      tumor stage, the longer was the TPSS, the better were the vital prognosis, the local and
      lymph node control. But there is no clear definition of fast growing tumor, with objective
      measurement.

      A CT-scan is perfomed at the time of diagnosis. Several weeks later, a second CT-scan is
      necessary for treatment planning in order to define the tumoral target volume. This necessity
      provides the opportunity to compare tumoral volumes on both exams, and thus to assess tumoral
      progression. In a pilot study conducted with Institut Gustave Roussy, the investigators
      studied retrospectively the tumor and loco-regional progression in the waiting time between
      diagnostic and treatment planning CT-scans in a cohort of patients with oropharyngeal
      squamous cell carcinoma, treated by radio(chemo)therapy between April 2005 and April 2007.
      The study demonstrated that 53% of the patients presented a tumoral progression of > 50%
      within a mean waiting time of 42.1 +/- 15.7 days. The investigators consider this situation
      as regrettable, and prospective trials are clearly needed to determine clinical consequences
      of these findings.

      The current project aims to study prospectively the loco-regional tumoral progression within
      the waiting time between diagnostic and treatment planning CT-scans in a cohort of patients
      with OPSCC. Patients with oropharyngeal primary squamous cell carcinoma elected for
      radiotherapy or radiochemotherapy with curative intent will be selected. Tumor volume, number
      and size of pathological cervical lymph nodes (small diameter > 1 cm) will be assessed on
      diagnostic CT-scan (DiCT) and treatment planning CT-scan (RtCT) using the summation of areas
      technique (computerized delineation). Tumoral progression and tumor doubling time will be
      calculated based on DiCT and RtCT in order to define different tumoral kinetics patterns.
      Human papillomavirus (HPV) status will be assessed by polymerase chain reaction (PCR) and p16
      immunohistochemistry. As primary objective, the investigators will study the tumoral kinetics
      patterns with disease free survival (DFS) and overall survival (OS) in patients with OPSCC in
      order to study their clinical signification [time frame: 5 years]. As secondary objectives,
      the investigators will correlate the tumoral kinetics patterns with HPV status of patients
      with OPSCC, and compare tumoural kinetics to proliferation markers (Ki67, mitotic index) in
      order to develop predictive markers of tumour progression for head and neck cancers. An other
      complementary objective will compare tumor kinetics patterns with endoscopic aspect
      (ulcerative versus exophytic)
observational model: Cohort
time perspective: Prospective
measure: overall survival
time frame: 5 years follow-up after recruitment
measure: disease-free survival
time frame: 5 years
measure: correlation between kinetics patterns and HPV status
time frame: 5y follow-up
measure: correlation between kinetics patterns and proliferation markers
time frame: 5y follow-up
measure: correlation between kinetics patterns and endoscopic aspect of the tumor
time frame: 5y follow-up
arm group label: head and neck squamous cell carcinoma
description: Patients with T1 to T4 head and neck squamous cell carcinoma from oral cavity, oropharynx, larynx and hypopharynx eligible for radiotherapy or concomitant chemoradiotherapy
intervention type: Other
intervention name: Tumor delineation
description: Measurement of tumor volume and neck nodes volume on a diagnostic CT and a pre-treatment CT by computerized delineation in order to calculate tumor growth velocity and tumor doubling time and describe tumoral kinetics patterns
arm group label: head and neck squamous cell carcinoma
Oropharynx biopsy
study pop: 
sampling method: Non-Probability Sample
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Sebastien Van der Vorst, MD, PhD
role: Principal Investigator
affiliation: CHU Dinant Godinne
last name: Sebastien Van der Vorst, MD, PhD
phone: +32 81 423726
email: sebastien.vandervorst@uclouvain.be
facility: 
contact: 
facility: 
contact: 
investigator: 
investigator: 
country: Belgium
citation: Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66. doi: 10.3322/canjclin.57.1.43.
PMID: 17237035
citation: Waaijer A, Terhaard CH, Dehnad H, Hordijk GJ, van Leeuwen MS, Raaymakers CP, Lagendijk JJ. Waiting times for radiotherapy: consequences of volume increase for the TCP in oropharyngeal carcinoma. Radiother Oncol. 2003 Mar;66(3):271-6. doi: 10.1016/s0167-8140(03)00036-7.
PMID: 12742266
citation: Jensen AR, Nellemann HM, Overgaard J. Tumor progression in waiting time for radiotherapy in head and neck cancer. Radiother Oncol. 2007 Jul;84(1):5-10. doi: 10.1016/j.radonc.2007.04.001. Epub 2007 May 9.
PMID: 17493700
citation: Brouha XD, Op De Coul B, Terhaard CH, Hordijk GJ. Does waiting time for radiotherapy affect local control of T1N0M0 glottic laryngeal carcinoma? Clin Otolaryngol Allied Sci. 2000 Jun;25(3):215-8. doi: 10.1046/j.1365-2273.2000.00347.x.
PMID: 10944052
citation: De Meerleer GO, Vakaet LA, De Gersem WR, De Wagter C, De Naeyer B, De Neve W. Radiotherapy of prostate cancer with or without intensity modulated beams: a planning comparison. Int J Radiat Oncol Biol Phys. 2000 Jun 1;47(3):639-48. doi: 10.1016/s0360-3016(00)00419-3.
PMID: 10837946
citation: Mackillop WJ, Zhou Y, Quirt CF. A comparison of delays in the treatment of cancer with radiation in Canada and the United States. Int J Radiat Oncol Biol Phys. 1995 May 15;32(2):531-9. doi: 10.1016/0360-3016(94)00662-5.
PMID: 7751195
citation: O'Rourke N, Edwards R. Lung cancer treatment waiting times and tumour growth. Clin Oncol (R Coll Radiol). 2000;12(3):141-4. doi: 10.1053/clon.2000.9139.
PMID: 10942328
citation: Primdahl H, Nielsen AL, Larsen S, Andersen E, Ipsen M, Lajer C, Vestermark LW, Andersen LJ, Hansen HS, Overgaard M, Overgaard J, Grau C; DAHANCA. Changes from 1992 to 2002 in the pretreatment delay for patients with squamous cell carcinoma of larynx or pharynx: a Danish nationwide survey from DAHANCA. Acta Oncol. 2006;45(2):156-61. doi: 10.1080/02841860500423948.
PMID: 16546860
citation: Robinson D, Massey T, Davies E, Jack RH, Sehgal A, Moller H. Waiting times for radiotherapy: variation over time and between cancer networks in southeast England. Br J Cancer. 2005 Apr 11;92(7):1201-8. doi: 10.1038/sj.bjc.6602463.
PMID: 15785752
responsible party type: Sponsor
mesh term: Carcinoma
mesh term: Neoplasms
mesh term: Carcinoma, Squamous Cell
mesh term: Squamous Cell Carcinoma of Head and Neck